Gaming and Leisure Properties Inc. Common Stock vs Incyte Corporation — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.45 (market cap $11.11B), while Incyte Corporation trades at $111.6 (market cap $22.63B). The key difference: Incyte Corporation is far larger — about 2× Gaming and Leisure Properties Inc. Common Stock's market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.59% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and Incyte Corporation for 33 Days on average.
| GLPI | INCY | |
|---|---|---|
Market Cap | $11.11B | $22.63B |
Volume | 2,244,030 | 1,869,988 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $129.93 |
52-Week Low | $37.59 | $86.17 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $19.17B | $18.13B |
Dividend Yield | 8.59% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →